OPKO Health generated $163.58 million of Revenue in the quarter, including $46.09 million from intellectual property and other sources. The company recorded an $8.416 million net loss and a $0.01 basic and diluted loss per share, giving investors a combined view of revenue production and quarterly profitability.
Key Highlights
- Product revenue reached $42.941 million, compared with $40.743 million in the comparable quarter.
- Revenue from intellectual property and other sources totaled $46.09 million, versus $14.963 million previously.
- Research and development spending was $33.166 million, compared with $30.342 million in the comparable quarter.
OPKO Health, Inc. (NASDAQ: OPK) recorded total revenue of $163.58 million for the three months ended June 30, 2026, compared with $156.807 million for the comparable period. Net loss was $8.416 million, while basic and diluted loss per share was $0.01. The reported revenue came from services, products, and the transfer of intellectual property and other sources.
Quarterly Costs And Loss
Total costs and expenses were $170.552 million, compared with $216.788 million in the comparable period. Cost of service revenue was $58.462 million, while cost of product revenue was $25.101 million.
Selling, general and administrative expense was $52.924 million. Research and Development expense reached $33.166 million, and amortization of intangible Assets was $18.969 million. The company also recorded a $18.07 million gain on the sale of assets.
Revenue Mix Shifts
Revenue from services was $74.549 million. Product revenue totaled $42.941 million, compared with $40.743 million in the comparable period.
Revenue from the transfer of intellectual property and other sources was $46.09 million, compared with $14.963 million previously.
Services And Operating Expenses
Diagnostics revenue consisted of service revenue of $74.549 million.
The diagnostics cost structure included $58.462 million of service revenue costs, alongside $52.924 million in company-wide selling, general and administrative expense and $33.166 million in research and development expense. Amortization of intangible assets contributed $18.969 million to quarterly costs.



Please wait processing your request...